Former Executive at Genzyme Corp. and Osiris Therapeutics, Inc. to Head Business Advisory Board at Rx for Africa, Inc.
NEW YORK, April 13 /PRNewswire-FirstCall/ -- A top biotech executive, William Pursley, has agreed to become Chairman of Rx for Africa, Inc.'s (Pink Sheets: RXAF) newly created Business Advisory Board. For 25 years Mr. Pursley has held major executive positions in the biotech industry. In 1985 he j...
JDRF Partners with Osiris to evaluate an immunomodulatory cell therapy product for type 1 diabetes
JDRF Partners with Osiris
on a Phase II Trial to Evaluate an Immunomodulatory Cell Therapy Product For Type 1 Diabetes
New York, NY October 25, 2007 The Juvenile Diabetes Research Foundation announced today a partnership with Osiris
Therapeutics, Inc. (NASDAQ:OSIR) to support a Phase II cli...
Biotech Osiris to go public
Baltimore biotech, the company that is known for being the sole manufacturer of the stem cell product, has made its plans known, about its intention to go public//. The company is slated to sell out nearly $80 million in shares, as per the papers filed with the Securities and Exchange Commission. ...
Long Term Supply of Osteocel(R) Plus Solidified Without Ownership of Processing Facility
...Vasive has accelerated the transfer of the processing of Osteocel Plus from osiris
Therapeutics (Nasdaq: OSIR ) to its own exclusive supply chain.
Sin...and consistent stream of supply. NuVasive will not assume ownership of the osiris
tissue processing facility.
NuVasive reiterates its previous guidance ...
Ongoing worldwide shortage of medical isotopes could threaten patient care, says expert
...ld's Mo-99 is produced by five commercial nuclear reactors NRU at Chalk River in Canada, HFR at Petten in The Netherland, BR-2 at Fleurus in Belgium, osiris
at Saclay in France and SAFARI-1 at Pelindaba in South Africa. The UK has no facility for producing Mo-99 of its own. Until fairly recently, productio...
BullMarket.com Examines Stem Cell Stocks
...ibers with coverage of stem cell stocks, including Geron (Nasdaq: GERN ), osiris
Therapeutics (Nasdaq: OSIR ), Cytori Therapeutics (Nasdaq: CYTX ), and ...ptions surrounding stem cell stocks?
-- What are some of the positives osiris
has going for it?
-- What potential problem could Cytori run into?
NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results
...nge of $345 million to $350 million. Osteocel revenue in the fourth quarter 2008 included approximately $5 million in sales to former distributors of osiris
Therapeutics, Inc. (Nasdaq: OSIR ). As the Company launches the Osteocel product through its exclusive sales force, it will not have the benefit of...
QRxPharma Expands Management Team with the Addition of Dr. Jesus Soriano as Executive Vice President
...o joining QRxPharma, Soriano was Senior Director of Business Development at osiris
Therapeutics, Inc., and responsible for all business development activities... out-licensing and divestiture. During Dr. Soriano's tenure, Maryland-based osiris
Therapeutics formed a $1.4 billion partnership with Genzyme Corp. for the d...
Stem Cell Product Commercialization Focus of Summit
...Inc. Novocell, Inc.
ArunA Biomedical, Inc. NuVasive, Inc.
BioE Corp. osiris
California Stem Cell, Inc. Progenitor Cell Therapy, Inc.
Cellerix, S.A. SpineSmit...
Preliminary Lineup Set for 4th Annual Stem Cell Summit
... Arteriocyte, Inc. Novocell, Inc. BioE Corp. NuVasive, Inc. California Stem Cell, Inc. osiris
Therapeutics, Inc. Cellerix, S.A. Progenitor Cell Therapy, Inc. Cognate BioServices, Inc. Stemagen Cytori Ther...
Osiris in Medical Technology
Pain Relief in Just One Visit with Genzyme's Synvisc-One
...ceuticals, Genzyme Biosurgery, Integra LifeSciences, LifeNet Health, Medtronic Spinal and Biologics, Musculoskeletal Transplant Foundation, Orthovita, osiris
Therapeutics, Osteotech, RTI Biologics, sanofi-aventis, Smith & Nephew, Stryker, Synthes, Wright Medical Technology, and many more. Other reports ...
Heart Attack Patients Treated With Novel Stem Cell Therapy
Experience Significant Improvement in Heart and Lung Function
...dical Center, we were able to conduct a study
that was exceptionally well planned and executed” said C.
Randal Mills Ph.D., President and CEO of osiris
“We were confident in the safety profile given our previous
experience using the intravenous form of these stem cells to treat
Osiris in Medical Products
is a system built around data management software and an imaging device that measures the inhibition zone size around an antibiotic disc. osiris
offers built-in expertise for detection of potential errors and detection o...
Osiris in Biological News
Osiris in Biological Technology
NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
- Expands biologics platform for robust growth -
- Includes proprietary adult stem cell bone graft product and processing facility -
- Expects Osteocel(R) revenues of $15 million in 2008 and $25 million in 2009; no dilution to earnings per share in...
NeoStem Featured in Business Week; 'Promising' Adult Stem Cell Market Discussed in Fortune-CNNMoney.com Article
...tal Partners, a Pan-Asian private equity firm with deep connections across Asia, declared, "I believe investors are beginning to see that, compared to osiris
-- which is the largest stem cell company with a market cap of around $425 million -- NBS is dramatically undervalued given its IP portfolio, product ...
AssureRx Adds New CEO
... the buyout of a New York Stock Exchange company to form MedPointe Pharmaceuticals.
Mr. Burns was also a founder, chairman, president and CEO of osiris
Therapeutics Inc., a public biotech company developing therapeutic stem-cell products for the regeneration of damaged or diseased tissues. Previously,...
Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phase II Trial
...o or animal. MSCs have the ability to develop into other types of cells and generate new tissue, including heart muscle. Prochymal(R) is a product of osiris
"There's a lot of enthusiasm in the cardiovascular community about the potential of stem cell therapies for treating heart dis...
Three Firms, Two Training Programs Garner Greater Baltimore Committee's 2009 Bioscience Awards
... Best New Product or Progress: C. Randal Mills, Ph.D., president and CEO, osiris
Therapeutics, Inc. Mills' Columbia-based company has spent more than $300 million developing stem cell therapies. The funding has allowed osiris
to complete clinical trials necessary to demonstrate the safety and efficac...
Greater Baltimore Committee to Announce Winners of 2009 Maryland Bioscience Awards at Ceremonies on March 12
Fred E. Festa , chairman, president and CEO, W.R. Grace & Company
Dr. C. Randal Mills , president and CEO, osiris
Dr. Bruce Thompson , chairman of the board and president, Clinical Trials and Surveys Corp. (C-TASC)
NuVasive Completes Acquisition of Osteocel Biologics Business
... surgical treatments for the spine, announced today
that it has completed the previously announced acquisition of the Osteocel
biologics business from osiris
Therapeutics, Inc. (Nasdaq: OSIR ) for $35
million in cash, plus additional milestone-based contingent payments not to
exceed $50 million in either c...
BioSpace Career Fair in Bethesda, Maryland Draws Hundreds of Industry Professionals
... biologists, chemists and many others attended to interview
with some of the top biotechnology companies and pharmaceutical firms.
Companies including osiris
Therapeutics and SAIC-Frederick were hiring for
biotech business development careers, pharmaceutical facility management
jobs, cell biology careers, b...
Stem Cell Therapy to Skyrocket by 2017
...dvanced Cell Technologies, Arteriocyte,
Blackstone Medical, Cytori Therapeutics, Geron, Harvest Technologies,
International Stem Cell Corporation, and osiris
Therapeutics. About Stem Cells Stem cells are primal cells that are derived from highly proliferative
tissues. These cells are precursors to every o...